Skip to content

Evaluation study to measure the cardiovascular risk of psoriasis patients and patients with atopic dermatitis in dermatological rehabilitation

Evaluation study to measure the cardiovascular risk of psoriasis patients and patients with atopic dermatitis in dermatological rehabilitation - KARPSOADReha

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00035242
Enrollment
100
Registered
2025-03-24
Start date
2025-02-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40 L20

Interventions

Group 1: Patients with psoriasis vulgaris or atopic dermatitis receiving dermatological rehabilitation will be informed on the day of admission. With consent, cardiorespiratory fitness will be measure

Sponsors

Fachklinik Bad Bentheim
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of atopic dermatitis or diagnosis of psoriasis

Exclusion criteria

Exclusion criteria: No inclusion of patients who, in the opinion of the enrolling physician, are unable to complete the questionnaires accurately and truthfully. No inclusion of individuals dependent on the sponsor, study director, or responsible physician. Individuals who are unable to provide consent are excluded from participation in the study.

Design outcomes

Primary

MeasureTime frame
Difference (performance improvement) in cardiorespiratory fitness measured by the steep ramp test (using a cycle ergometer) on days 1 and 21 of dermatological rehabilitation.

Secondary

MeasureTime frame
ESC SCORE2/SCORE2-OP, blood pressure, pulse, weight, BMI, waist circumference, fasting blood glucose, laboratory parameters: triglycerides, total cholesterol, LDL, HDL, GOT, GPT, GGT, HbA1c, vitamin D, alkaline phosphatase, bilirubin, creatinine, GFR, NT-proBNP, hsCRP, neopterin, lipoprotein (a), IL-6, uric acid. DLQI (Quality of Life), PASI (Disease Activity of Psoriasis) / EASI (Disease Activity of Atopic Dermatitis) / SCORAD (disease activity of atopic dermatitis), Patient's Global Assessment of Psoriasis (patient’s own assessment of psoriasis disease activity) / Patient's Global Assessment of Atopic Dermatitis (patient’s own assessment of atopic dermatitis disease activity), NRS for pruritus (mean and maximum), subjective treatment success, satisfaction with therapeutic options in rehabilitation.

Countries

Germany

Contacts

Public ContactAthanasios Tsianakas

Fachklinik Bad Bentheim

a.tsianakas@fk-bentheim.de(05922) 74-52 10

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026